Comparison of Sublingual Misoprostol and Intravenous Oxytocin in Active Management of the Third Stage of Labor

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01612390

Enrollment

180

Registered

2012-06-05

Start date

2012-08-31

Completion date

2013-12-31

Last updated

2012-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum Hemorrhage Prevention by Using Oxytocin Verses Misoprostol

Keywords

postpartum hemorrhage

Brief summary

Sublingual misoprostol is superior to oxytocin in reduction of blood loss during the third and fourth stages of labor

Detailed description

Sublingual misoprostol is superior to oxytocin in reduction of blood loss during the third and fourth stages of labor as The data from a pharmacokinetics study suggested that the bioavaiblitiy of misoprostol after sub-lingual administration was higher than those after oral or vaginal administration

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Women with aheathy singleton pregnancy in spontaneous or induced labor at term .

Exclusion criteria

* Hypersensitivity/Contraindication to prostaglandins Antepartum hemorrhage Multiple pregnancy Cardiac disease Malpresentation Rhesus- negative mother hypersensitive disorders Severe anaemia(hemoglobin\<7g/dl)

Design outcomes

Primary

Measure	Time frame	Description
reduce blood loss during third and fourth stages of labor.	1 year	reduce blood loss during third and fourth stages of labor by using misopristol is better than using oxytocin

Secondary

Measure	Time frame	Description
the duration of the third stage of labor ,need for oxytocics ,blood transfusion and any adverse effects of the drugs	1 year	the duration of the third stage of labor ,needed for oxytocics ,blood transfusion and any adverse effects of the drug will be reduced with mesopristol

Countries

Egypt

Contacts

Primary ContactRasha mohamed, M.B;B.CH

abosalma_82@yahoo.com

Outcome results